Resistant Hypertension – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Resistant Hypertension – Pipeline Review, H2 2016’, provides an overview of the Resistant Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Resistant Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Resistant Hypertension and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Resistant Hypertension

The report reviews pipeline therapeutics for Resistant Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Resistant Hypertension therapeutics and enlists all their major and minor projects

The report assesses Resistant Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Resistant Hypertension

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Resistant Hypertension

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Resistant Hypertension pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Bayer AG

Novartis AG

Sarfez Pharmaceuticals Inc

PhaseBio Pharmaceuticals Inc

Zumbro Discovery Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Resistant Hypertension Overview 6

Pipeline Products for Resistant Hypertension - Overview 7

Resistant Hypertension - Therapeutics under Development by Companies 8

Resistant Hypertension - Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Resistant Hypertension - Products under Development by Companies 11

Resistant Hypertension - Companies Involved in Therapeutics Development 12

Bayer AG 12

Novartis AG 13

Sarfez Pharmaceuticals Inc 14

PhaseBio Pharmaceuticals Inc 15

Zumbro Discovery Inc 16

Resistant Hypertension - Therapeutics Assessment 17

Assessment by Monotherapy Products 17

Assessment by Target 18

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Drug Profiles 26

BAY-1636183 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

LHW-090 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

PB-1120 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

SP-20203 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

ZD-100 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Resistant Hypertension - Dormant Projects 31

Resistant Hypertension - Discontinued Products 32

Appendix 33

Methodology 33

Coverage 33

Secondary Research 33

Primary Research 33

Expert Panel Validation 33

Contact Us 33

Disclaimer 34

List of Tables

List of Tables

Number of Products under Development for Resistant Hypertension, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Development, H2 2016 10

Products under Development by Companies, H2 2016 11

Resistant Hypertension – Pipeline by Bayer AG, H2 2016 12

Resistant Hypertension – Pipeline by Novartis AG, H2 2016 13

Resistant Hypertension – Pipeline by Sarfez Pharmaceuticals Inc, H2 2016 14

Resistant Hypertension – Pipeline by PhaseBio Pharmaceuticals Inc, H2 2016 15

Resistant Hypertension – Pipeline by Zumbro Discovery Inc, H2 2016 16

Assessment by Monotherapy Products, H2 2016 17

Number of Products by Stage and Target, H2 2016 19

Number of Products by Stage and Mechanism of Action, H2 2016 21

Number of Products by Stage and Route of Administration, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 25

Resistant Hypertension – Dormant Projects, H2 2016 31

Resistant Hypertension – Discontinued Products, H2 2016 32

List of Figures

List of Figures

Number of Products under Development for Resistant Hypertension, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 10

Assessment by Monotherapy Products, H2 2016 17

Number of Products by Targets, H2 2016 18

Number of Products by Stage and Targets, H2 2016 18

Number of Products by Mechanism of Actions, H2 2016 20

Number of Products by Stage and Mechanism of Actions, H2 2016 20

Number of Products by Routes of Administration, H2 2016 22

Number of Products by Stage and Routes of Administration, H2 2016 22

Number of Products by Molecule Types, H2 2016 24

Number of Products by Stage and Molecule Types, H2 2016 24

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports